{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T19:51:03Z","timestamp":1791661863558,"version":"4.3.4"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jcf.2026.10.001","type":"journal-article","created":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T19:28:36Z","timestamp":1791660516000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Perspectives on inhaled medicines in the CFTR modulator era: A national survey of adults with cystic fibrosis"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6933-9921","authenticated-orcid":false,"given":"R.D.","family":"Sandler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7067-3783","authenticated-orcid":false,"given":"Z.H.","family":"Hoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5557-4613","authenticated-orcid":false,"given":"S.M.B","family":"Ariss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2026.10.001_bib0001","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.jcf.2024.09.024","article-title":"Room to breathe: the promise of a more flexible cystic fibrosis care model","volume":"23","author":"Bruening Wajda","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.jcf.2026.10.001_bib0002","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jcf.2021.08.014","article-title":"Treatment patterns in people with cystic fibrosis: have they changed since the introduction of ivacaftor?","volume":"21","author":"Granger","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.10.001_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2023.102264","article-title":"Medication use in people with cystic fibrosis before and after modulator therapy","volume":"83","author":"Lord","year":"2023","journal-title":"Pulm Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.jcf.2026.10.001_bib0004","article-title":"Exploring the impact of elexacaftor-tezacaftor-ivacaftor treatment on opinions regarding airway clearance techniques and nebulisers: TEMPO a qualitative study in children with cystic fibrosis, their families and healthcare professionals","volume":"9","author":"Almulhem","year":"2022","journal-title":"BMJ Open Respir Res"},{"key":"10.1016\/j.jcf.2026.10.001_bib0005","article-title":"The psychological implications and health risks of cystic fibrosis pre- and post- CFTR modulator therapy","author":"Keyte","year":"2022","journal-title":"Chronic Illn"},{"issue":"6","key":"10.1016\/j.jcf.2026.10.001_bib0006","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.chest.2022.07.008","article-title":"Treatment preference among people with cystic fibrosis: the importance of reducing Treatment burden","volume":"162","author":"Cameron","year":"2022","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.jcf.2026.10.001_bib0007","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1177\/1359105320916539","article-title":"How do cystic fibrosis patients experience parenthood? A systematic review","volume":"26","author":"Jacob","year":"2021","journal-title":"J Health Psychol"},{"issue":"1","key":"10.1016\/j.jcf.2026.10.001_bib0008","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.pec.2009.03.022","article-title":"The effect of physician-patient collaboration on patient adherence in non-psychiatric medicine","volume":"77","author":"Arbuthnott","year":"2009","journal-title":"Patient Educ Couns"},{"issue":"8","key":"10.1016\/j.jcf.2026.10.001_bib0009","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1093\/jpepsy\/jsn135","article-title":"Adherence to treatment in adolescents with cystic fibrosis: the role of illness perceptions and treatment beliefs","volume":"34","author":"Bucks","year":"2009","journal-title":"J Pediatr Psychol"},{"key":"10.1016\/j.jcf.2026.10.001_bib0010","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12890-015-0038-7","article-title":"Adherence to treatment in children and adolescents with cystic fibrosis: a cross-sectional, multi-method study investigating the influence of beliefs about treatment and parental depressive symptoms","volume":"15","author":"Goodfellow","year":"2015","journal-title":"BMC Pulm Med"},{"issue":"2","key":"10.1016\/j.jcf.2026.10.001_bib0011","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1136\/thoraxjnl-2017-211453","article-title":"Role of habit in treatment adherence among adults with cystic fibrosis","volume":"74","author":"Hoo","year":"2019","journal-title":"Thorax"},{"issue":"5","key":"10.1016\/j.jcf.2026.10.001_bib0012","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.jcf.2026.05.012","article-title":"Factors associated with adherence to inhaled medicines in cystic fibrosis following the introduction of elexacaftor\/tezacaftor\/ivacaftor using electronically captured adherence data","volume":"25","author":"Sandler","year":"2026","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.jcf.2026.10.001_bib0013","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/17476348.2017.1280399","article-title":"Adherence to therapies in cystic fibrosis: a targeted literature review","volume":"11","author":"Narayanan","year":"2017","journal-title":"Expert Rev Respir Med"},{"key":"10.1016\/j.jcf.2026.10.001_bib0014","series-title":"The health belief model of behavior change. statpearls [Internet]","author":"Alyafei","year":"2024"},{"key":"10.1016\/j.jcf.2026.10.001_bib0015","doi-asserted-by":"crossref","DOI":"10.1177\/20406223241264477","article-title":"The impact of elexacaftor\/tezacaftor\/ivacaftor on cystic fibrosis health-related quality of life and decision-making about daily treatment regimens: a mixed methods exploratory study","volume":"15","author":"Basile","year":"2024","journal-title":"Ther Adv Chronic Dis"},{"issue":"3","key":"10.1016\/j.jcf.2026.10.001_bib0016","first-page":"189","article-title":"The challenge of patient adherence","volume":"1","author":"Martin","year":"2005","journal-title":"Ther Clin Risk Manag"},{"issue":"8","key":"10.1016\/j.jcf.2026.10.001_bib0017","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1097\/MLR.0b013e31819a5acc","article-title":"Physician communication and patient adherence to treatment: a meta-analysis","volume":"47","author":"Zolnierek","year":"2009","journal-title":"Med Care"},{"issue":"1","key":"10.1016\/j.jcf.2026.10.001_bib0018","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1185\/03007990802619425","article-title":"The adherence estimator: a brief, proximal screener for patient propensity to adhere to prescription medications for chronic disease","volume":"25","author":"McHorney","year":"2009","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"10.1016\/j.jcf.2026.10.001_bib0019","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jcf.2018.02.006","article-title":"ECFS best practice guidelines: the 2018 revision","volume":"17","author":"Castellani","year":"2018","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.10.001_bib0020","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jcf.2024.01.005","article-title":"Standards for the care of people with cystic fibrosis (CF); recognising and addressing CF health issues","volume":"23","author":"Burgel","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2026.10.001_bib0021","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jcf.2023.12.002","article-title":"Standards for the care of people with cystic fibrosis; establishing and maintaining health","volume":"23","author":"Southern","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.10.001_bib0022","article-title":"Self-reported chronic therapy use after 24-weeks of follow-up by participants who completed the simplify randomized, controlled trial","author":"Gifford","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.10.001_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2025.107995","article-title":"Optimising outcomes for adults with cystic fibrosis taking CFTR modulators by individualising care: personalised data linkage to understand treatment optimisation (PLUTO), a novel clinical framework","volume":"239","author":"Sandler","year":"2025","journal-title":"Respir Med"},{"issue":"167","key":"10.1016\/j.jcf.2026.10.001_bib0024","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0154-2022","article-title":"Role of inhaled antibiotics in the era of highly effective CFTR modulators","volume":"32","author":"Elborn","year":"2023","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.jcf.2026.10.001_bib0025","first-page":"3","article-title":"Detection of Pseudomonas aeruginosa in cystic fibrosis after initiation of CFTR modulators: a systematic review","volume":"59","author":"Terlizzi","year":"2026","journal-title":"Paediatr Respir Rev"},{"key":"10.1016\/j.jcf.2026.10.001_bib0026","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1163391","article-title":"Real-world disparities and ethical considerations with access to CFTR modulator drugs: mind the gap!","volume":"14","author":"Zampoli","year":"2023","journal-title":"Front Pharmacol"},{"issue":"Suppl 3","key":"10.1016\/j.jcf.2026.10.001_bib0027","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jcf.2021.09.005","article-title":"Patient and family experience of telehealth care delivery as part of the CF chronic care model early in the COVID-19 pandemic","volume":"20","author":"Solomon","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.10.001_bib0028","article-title":"Cystic fibrosis experience of care survey: patient-caregiver-clinician collaborative design and implementation","volume":"11","author":"Allen","year":"2024","journal-title":"J Patient Exp"},{"issue":"1","key":"10.1016\/j.jcf.2026.10.001_bib0029","article-title":"CFDigiCare. The CFHealthHub learning health system: using real-time adherence data to support a community of practice to deliver continuous improvement in an archetypal long-term condition","volume":"11","author":"Sandler","year":"2022","journal-title":"Healthcare (Basel)"},{"issue":"1","key":"10.1016\/j.jcf.2026.10.001_bib0030","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1164\/rccm.200502-273OC","article-title":"Clinical trial participants compared with nonparticipants in cystic fibrosis","volume":"173","author":"Goss","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.jcf.2026.10.001_bib0031","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1037\/hea0000136","article-title":"Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis","volume":"34","author":"Hilliard","year":"2015","journal-title":"Health Psychol"},{"issue":"4","key":"10.1016\/j.jcf.2026.10.001_bib0032","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1007\/s10880-018-9598-z","article-title":"Identifying factors that facilitate treatment adherence in cystic fibrosis: qualitative analyses of interviews with parents and adolescents","volume":"26","author":"Nicolais","year":"2019","journal-title":"J Clin Psychol Med Settings"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199326037719?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199326037719?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T19:28:40Z","timestamp":1791660520000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199326037719"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":32,"alternative-id":["S1569199326037719"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2026.10.001","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Perspectives on inhaled medicines in the CFTR modulator era: A national survey of adults with cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2026.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}